Drug intelligence / Profile preview

ONC-01

Development stage: Preclinical
Lead developer: Immunome

Overview

ONC-01 is an investigational drug candidate under development by Immunome, a biotechnology company focused on targeted cancer therapies. The program for ONC-01 involves activities such as IND submission, communications with the FDA, securing clinical drug supply, and ensuring clinical trial readiness, indicating it is in preclinical or early clinical development for cancer indications.

Beyond the preview

Go deeper on ONC-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONC-01.

Explore the full profile